
|Articles|November 29, 2012
New drug promising for psoriatic arthritis
An oral phosphodiesterase 4 inhibitor may offer significant improvement in signs and symptoms of psoriatic arthritis, according to preliminary trial data.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
2
Kyowa Kirin Takes Full Control of Rocatinlimab Program
3
FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA
4
Dermatology Times January 2026 Recap
5











